Patents Examined by Sun Jae Yoo
  • BCL-2 inhibitors
    Patent number: 11365206
    Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neurodegenerative disease with these compounds.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: June 21, 2022
    Assignee: Newave Pharmaceutical Inc.
    Inventors: Yi Chen, Yan Lou
  • Selective HDAC6 inhibitors
    Patent number: 11351178
    Abstract: The present invention relates to novel benzohydroxamic compounds of formula (I) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (HDAC6) enzyme.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: June 7, 2022
    Assignee: ITALFARMACO SPA
    Inventors: Barbara Vergani, Gianluca Caprini, Gianluca Fossati, Maria Lattanzio, Mattia Marchini, Gianfranco Pavich, Marcello Pezzuto, Chiara Ripamonti, Giovanni Sandrone, Christian Steinkühler, Andrea Stevenazzi
  • Antitumoral compounds
    Patent number: 11339180
    Abstract: A compound of general formula I and pharmaceutical compositions, kits, methods of making, and methods for treating cancer using the same.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: May 24, 2022
    Assignee: PHARMA MAR, S.A.
    Inventors: María del Carmen Cuevas Marchante, Andrés Francesch Solloso, Valentín Martínez Barrasa
  • Antitumoral compounds
    Patent number: 11332480
    Abstract: A compound of general formula I, wherein X, R1-R4 take various meanings, for use in the treatment of cancer.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 17, 2022
    Assignee: PHARMA MAR, S.A.
    Inventors: María del Carmen Cuevas Marchante, Andrés Francesch Solloso, Valentín Martínez Barrasa
  • YAP1 inhibitors and methods
    Patent number: 11331304
    Abstract: YAP1 inhibitors and methods of treating a subject with a cancer that include administering a YAP1 inhibitor are disclosed. Also disclosed are methods for determining responsiveness to a YAP1 inhibitor in a subject, methods for diagnosing a tumor in a subject including determining the level of YAP1 expression, compositions that include YAP1 inhibitors, and methods of using those compositions.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: May 17, 2022
    Assignee: The Jackson Laboratory
    Inventors: Kyuson Yun, Hai-Xiao Zhai
  • 4-oxo-alkylated tetramic acid compound, and preparation method thereof
    Patent number: 11332440
    Abstract: The present invention relates to a new compound and a preparation method thereof. The general structural formula of the compound is shown in Formula I. Animal experiments show that the compound has the effect of saving the memory of animal models. It is of high safety, has no mutagenicity, can remain in blood for several hours after oral or intravenous injection, and can enter the brain. The compound can be used for preparing a medicament for treating Alzheimer's disease.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: May 17, 2022
    Assignee: BEIJING JOEKAI BIOTECH. LLC
    Inventors: Shuwen Du, Zuolei Xie
  • Method for treating stomach cancer
    Patent number: 11325885
    Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: May 10, 2022
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Maan T. Khayat, Dhaval Shah, Martin K. Safo, Azizah M. Malebari, Farid Ahmed
  • Timosaponin compounds
    Patent number: 11319338
    Abstract: Provided herein are timosaponin compounds of Formula I, II, III, I?, II? and III?, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are uses of said timosaponin compounds for preparing medicament for the treatment of diseases associated with beta-amyloid in hosts or subjects in need thereof.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: May 3, 2022
    Assignee: GoldPorp Pharma Limited
    Inventors: Chiming Che, Laiking Sy, Chunnam Lok
  • Polyfluoro-substituted aromatic heterocyclic derivative, pharmaceutical composition containing same, and applications thereof
    Patent number: 11319300
    Abstract: A polyfluoro-substituted aromatic heterocyclic derivative having the structure as represented by formula I or formula I?, wherein at least one of R1 and R2 is a fluorine atom, and at least two substituents of Rc, Rd, Re, and Rf are fluorine atoms; and an optical isomer of the derivative, or a pharmaceutically acceptable salt or solvate of the same, or a pharmaceutically acceptable salt or solvate of the optical isomer of the same. A composition containing the polyfluoro-substituted aromatic heterocyclic derivative and an application of the composition in preparing an anti-tumour medicament. The compound provides significant inhibitory effects with respect to Akt1 and demonstrates strong proliferation inhibitory activity with respect to tumour cell lines such as an ovarian cancer cell line, a colon cancer cell line, and a prostate cancer cell line.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: May 3, 2022
    Assignee: GUANGZHOU LIXIN PHARMACEUTICAL CO., LTD.
    Inventors: Xiaowu Dong, Bo Yang, Yongzhou Hu, Qiaojun He, Qinjie Weng, Wenhu Zhan, Tao Liu
  • Molecular host frameworks and methods of making and using same
    Patent number: 11312681
    Abstract: Crystalline molecular framework:small molecule compounds. The molecular framework is formed from guanidinium cations and organosulfonate anions and the guanidinium cations and organosulfonate anions are associated via one or more hydrogen bond. The small molecule(s) is/are encapsulated by the molecular framework. Methods for making crystalline molecular framework:small molecule compounds may include combining guanidinium cations, organosulfonate anions, and small molecules in a single step. The crystalline molecular framework:small molecule compounds can be used to determine the structure of the small molecule(s).
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: April 26, 2022
    Assignee: New York University
    Inventors: Michael David Ward, Yuantao Li, Chunhua Tony Hu
  • Method for treating a patient having a colon cancer
    Patent number: 11312680
    Abstract: Therapeutic compounds containing a phenyl core and amide link(s). Also described are pharmaceutical compositions incorporating the therapeutic compounds and a method for treating cancer with the compounds. These compounds are cytotoxic to stomach, colon, breast, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: April 26, 2022
    Assignee: King Abdulaziz University
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Maan T. Khayat, Dhaval Shah, Martin K. Safo, Azizah M. Malebari, Farid Ahmed
  • 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors
    Patent number: 11299480
    Abstract: The present disclosure provides pharmaceutical compositions comprising 2-arylsulfonamido-N-arylacetamide derivatized Stat3 inhibitors and certain pharmaceutically acceptable salts thereof, and methods of their use.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: April 12, 2022
    Assignee: University of Hawaii
    Inventors: James Turkson, Peibin Yue, Marcus Tius, Christine Brotherton-Pleiss, Francisco Javier Lopez Tapia
  • Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses
    Patent number: 11292781
    Abstract: Disclosed herein are compounds of the formulas: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to inhibit ROR? and/or reduce the expression of IL-17. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or autoimmune disorders.
    Type: Grant
    Filed: December 16, 2017
    Date of Patent: April 5, 2022
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Xin Jiang, Christopher F. Bender, Melean Visnick, Martha R. Hotema, Zachary S. Sheldon, Chitase Lee, Bradley William Caprathe, Gary Bolton, Brian Kornberg
  • Potassium channel inhibitors
    Patent number: 11274092
    Abstract: The present invention relates to a compound of the general formula (I). The compounds of formula I are useful for treatment of a cardiac disease, disorder or condition in a mammal.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: March 15, 2022
    Assignee: ACESION PHARMA ApS
    Inventors: Ulrik Svane Sørensen, Antonio Mete
  • Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2? inhibitors
    Patent number: 11267782
    Abstract: The present disclosure provides certain tetrahydro-1H-cyclopenta[cd]indene compounds that are Hypoxia Inducible Factor 2? (HIF-2?) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2?. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: March 8, 2022
    Assignee: NIKANG THERAPEUTICS, INC.
    Inventors: Jiping Fu, Yan Lou, Yigang He
  • Cannabis thin layer decarboxylation
    Patent number: 11254633
    Abstract: Dried and or decarboxylated cannabis containing a known composition of cannabinoids is blended with other dried or decarboxylated cannabis of a known composition of cannabinoids and or mixed with other extracts of, isolates of, cannabisor synthetic cannabinoids to achieve a prescribed amount of cannabinoids in the blend. Decarboxylated cannabis is preferentially produced using controlled thin layer decarboxylation. Precision decarboxylation is optionally used to produce a precise pair ratio of acidic to neutral cannabinoid, eg THCA to THC or CBDA to CBD. Further a prescribed or selected terpene profile is mixed and applied to the blend. Once mixed the plant material is suitable for ingestion without further treatment and is dosed appropriately.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: February 22, 2022
    Inventor: Jonas Alcirdas Navickas
  • MPO inhibitors for use in medicine
    Patent number: 11246870
    Abstract: The present disclosure relates to new therapeutic uses of MPO inhibitors and methods of treatment involving the same.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: February 15, 2022
    Assignee: ASTRAZENCA AB
    Inventors: Andrew Whittaker, Hitesh Jayantilal Sanganee
  • EBNA1 inhibitor crystalline forms, and methods of preparing and using same
    Patent number: 11242338
    Abstract: The invention relates, in certain aspects, to developable forms of certain compounds that are useful to treat and/or prevent EBV infection and related conditions in a subject. The invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: February 8, 2022
    Assignee: The Wistar Institute
    Inventors: Troy E. Messick, Paul M. Lieberman, Garry R. Smith, Arlindo L. Castelhano
  • Isoxazole compounds as inhibitors of heat shock proteins
    Patent number: 11234987
    Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C?O)—, —(C?S)—, —SO.sub.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: February 1, 2022
    Assignees: Cancer Research Technology Limited, The Institute of Cancer Research, Vernalis (R&D) Limited
    Inventors: Martin James Drysdale, Brian William Dymock, Harry Finch, Paul Webb, Edward McDonald, Karen Elizabeth James, Kwai Ming Cheung, Thomas Peter Matthews
  • TRPV4 antagonists
    Patent number: 11229623
    Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: January 25, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Edward J. Brnardic, Carl A. Brooks, Brian Griffin Lawhorn, Guosen Ye, Linda S. Barton, Brian W. Budzik, Jay M. Matthews, John Jeffrey McAtee, Jaclyn R. Patterson, Joseph E. Pero, Robert Sanchez, Matthew Robert Sender, Lamont Roscoe Terrell, David J. Behm, James V. Thomas